Clumping factor A

Protein mechanism

ClfA is a surface protein anchored to the cell wall of Staphylococcus aureus and is part of the MSCRAMM family, which helps the bacterium attach to host proteins. Its main target is the C-terminal part of the gamma chain of fibrinogen. The bond between ClfA and fibrinogen gets much stronger when mechanical force is applied. At low tension, the interaction is weak, around 0.1 nN, but under high force it jumps to about 1.5 nN, a classic catch-bond effect.

ClfA appears to have two binding sites for fibrinogen: one with low affinity that works under little force, and another with high affinity that activates under mechanical stress. At low force, fibrinogen may attach near the top of the N3 domain. This mechanical regulation lets S. aureus stick more firmly as shear stress rises, such as in flowing blood or on devices like pacemakers and catheters.

Structure

Clumping factor A’s ligand-binding region, known as the A region, is built from three subdomains called N1, N2, and N3. Its secondary structure features beta-pleated sheets and short alpha helices.

Fibrinogen is made of three paired polypeptide chains—Aα, Bβ, and γ—linked by disulfide bridges near the N-terminus. Its secondary structure also includes alpha helices and beta-pleated sheets. The tertiary structure of fibrinogen folds into three domains: the E domain, which holds fibrinopeptides A and B; the D domain, where the γ-chain C-terminus provides the binding site for ClfA; and a connector region that joins the N-terminal and C-terminal domains of each chain.

Biological functions

ClfA's main function is binding the host blood plasma protein fibrinogen, specifically the extreme C-terminal region of the fibrinogen γ-chain. It acts as a force-sensitive molecular switch: under physiological stress such as blood flow, the binding becomes stronger due to catch-bond behavior, enabling S. aureus to remain attached under high mechanical stress.

ClfA facilitates biofilm formation by binding to host fibrinogen, allowing the bacterium to attach to surfaces like medical devices and damaged tissues; the bacteria then proliferate and produce an extracellular matrix, forming a biofilm that protects them from antibiotics and immune responses. During blood flow, ClfA also enables S. aureus to bind to vascular endothelial cells, contributing to bloodstream infections. Additionally, ClfA serves as the bacterial partner for von Willebrand factor-binding protein (vWbp), which connects to von Willebrand factor (VWF), helping the bacteria attach to blood vessel walls.

Medical relevance

Clumping factor A, or ClfA, is considered an important target for treatments against Staphylococcus aureus because it plays a major role in the bacterium's ability to cause disease. Pfizer included ClfA in a vaccine designed to target multiple bacterial components. In animal studies, ClfA was shown to offer protection against arthritis, sepsis, and endocarditis.

Another study in a mouse mastitis model found that combining ClfA with the CP5 antigen reduced bacterial infection. ClfA was also tested in Veronate, a product made from human antibodies, but this did not lower the rate of staph sepsis in newborns. Additionally, antibodies against ClfA were found to protect against infections linked to biofilms in animal models.

Did You Know?

• ClfA also binds to complement regulator I protein.
• ClfA-induced bacterial aggregation forms large clumps that are physically more difficult for neutrophils and macrophages to engulf.
• ClfA interacts with complement factor I, an enzyme that cleaves C3b into its inactive form iC3b, reducing opsonization and preventing assembly of the membrane attack complex.